Skip to Navigation Skip to Search Skip to Content
Search All Centers

FDA Approvals in Hematology and Oncology

Published on January 24, 2020

In the last four months of 2019, the U.S. Food & Drug Administration approved 16 new drugs in the field of hematology and oncology. This is exciting news for cancer patients, because it means treatment options are continuing to evolve. From the approval of acalabrutinib (Calquence) for the treatment of chronic lymphocytic leukemia (CLL) to an accelerated approval of zanubrutinib (Brukinsa) for the treatment of mantle cell lymphoma, we have a lot of promising news to share.

After reviewing all of the recent FDA approvals, here are the seven most relevant to our Patient Power communities. Click on the links for more details:

BREAST CANCER

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

LUNG CANCER

MANTLE CELL LYMPHOMA

MULTIPLE MYELOMA

PROSTATE CANCER

 

For more information and a complete list of FDA-approved drugs, visit the U.S. Food & Drug Administration’s Hematology/Oncology page at FDA.gov. To receive emerging news and research updates, subscribe to our Patient Power eNews and follow us on Facebook


Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Featuring

You might also like